Results 241 to 250 of about 25,190 (292)
Some of the next articles are maybe not open access.

Desmopressin and Hypotension

Annals of Internal Medicine, 1985
Excerpt To the editor: In the review on desmopressin in the August issue (1), the scarcity of side effects is justly emphasized.
Frans H.M. Derkx   +2 more
openaire   +2 more sources

Pharmacokinetics of Desmopressin [PDF]

open access: possible, 1993
In 1967 Zaoral and coworkers synthesized several analogues of vasopressin. One of these derivatives, 1-deamino-8-D-arginine vasopressin (DDAVP, desmopressin), soon became the treatment of choice for diabetes insipidus centralis. DDAVP has a prolonged half-life and a decreased pressor activity when compared with the parent hormone vasopressin (VP). This
M. Köhler, Harris Alan
openaire   +1 more source

Differential Osteoprotegerin Kinetics after Stimulation with Desmopressin and Lipopolysaccharides In Vivo

Thrombosis and Haemostasis, 2020
Osteoprotegerin (OPG) regulates bone metabolism by reducing the activation of osteoclasts, but may also be involved in blood vessel calcification and atherosclerosis. Within endothelial cells OPG is stored in Weibel–Palade bodies (WPBs).
Nina Buchtele   +8 more
semanticscholar   +1 more source

Retrospective Assessment of Desmopressin Effectiveness and Safety in Patients With Antiplatelet-Associated Intracranial Hemorrhage.

Critical Care Medicine, 2019
OBJECTIVE Current international guidelines offer a conditional recommendation to consider a single dose of IV desmopressin (DDAVP) for antiplatelet-associated intracranial hemorrhage based on low-quality evidence.
E. Feldman   +9 more
semanticscholar   +1 more source

DESMOPRESSIN AND ANTIFIBRINOLYTICS

International Anesthesiology Clinics, 1990
Desmopressin appears to be a safe and effective hemostatic agent for use during surgery in patients with mild to moderate hemophilia or von Willebrand disease. Uremic patients also benefit from substitution of desmopressin for cryoprecipitate to control bleeding. The highly variable response to desmopressin by individual patients with hemophilia or von
openaire   +2 more sources

Desmopressin and hemostasis

Regulatory Peptides, 1993
Since it has been synthetized in 1967, desmopressin (Minirin) R or DDAVP (1-desamino-8-Darginine vasopressin) was initially used for its antidiuretic properties [1]. Its capacity to induce an increase in plasma level of procoagulant factor VIII C (FVIII C), von Willebrand factor (vWF) and plasminogen activator was recognized in the following years [2,3]
openaire   +3 more sources

OXYBUTYNIN, DESMOPRESSIN AND ENURESIS

The Journal of Urology, 2001
A review of the scarce literature concerning oxybutynin treatment for nocturnal enuresis reveals that its success is greatest when enuresis is combined with daytime incontinence. The renal and bladder related characteristics of children with monosymptomatic enuresis responsive to oxybutynin were evaluated.Renal concentrating capacity and functional ...
openaire   +3 more sources

Desmopressin and Blood Loss

Annals of Internal Medicine, 1988
Excerpt To the editor: Kobrinsky and associates (1) show that patients receiving 1-desamino-8-D-arginine vasopressin (desmopressin) had a decreased blood loss during Harrington rod spinal fusion su...
openaire   +3 more sources

The use of desmopressin in mild hemophilia A

Blood Coagulation & Fibrinolysis, 2010
Owing to its ability to raise plasma levels of factor VIII and von Willebrand factor levels, the synthetic vasopressin analogue desmopressin has become the mainstay of treatment for type 1 von Willebrand disease and mild hemophilia A. A long clinical experience with this drug for prevention or treatment of bleedings in these patients has been ...
Franchini M., Zaffanello M., Lippi G.
openaire   +3 more sources

Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta‐analysis

BJU International, 2018
To assess the efficacy of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agent (AA) therapy in the management of paediatric monosymptomatic nocturnal enuresis (MNE) using a network meta‐analysis.
Pan Song   +11 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy